● Sponsor: Cerevance
● General Summary of Trial: Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications
● Study Drug: Adjunctive therapy, a non-Dopaminergic, G-Protein Coupled Receptor (GPR6), inverse agonist also called, Solengepras. It’s a tablet that is orally administered every day.
● Looking to target: Patients with PD that experience OFF periods/motor complications.
● Length 16-21 weeks of participation
● 30 y/o , no DBS patients

● Sponsor: Amneal
● General Summary: Phase 4 Study IPX203-401-23 is designed as an open-label, multi-center Phase 4 study to evaluate the efficacy and safety of CREXONT under real world conditions in patients with PD, who will be treated as appropriate for their condition and guided by the United States (US) FDA approved CREXONT Prescribing Information.
● Study Product: Carbidopa-Levodopa Extended-Release Capsules orally administered.
● Target Population: Patients with moderately severe PD patients who experience motor complications, such as dyskinesias and OFF period episodes of at least 2.5hrs/day
● Length: 13-14 months, 10 visits
● Patients who have done Deep brain stimulation (DBS) are excluded from this trial.

● Sponsor: AbbVie
● General Summary: A Global Real-World Evidence Study on the long-term effectiveness of ABBV-951 in Advanced Parkinson´s Disease in routine clinical practice (ROSSINI: Real-world Outcomes with continuous Subcutaneous levodopa Infusion)
● Study Product: Continuous subcutaneous Foslevadopa/Foscarbidopa Infusion
● Targeting: Pts with advanced PD, that experience motor complications/OFF periods and dyskinesia everyday
● 18 y/o or older, DBS patients are welcome
● Length: 3+ years, 10 visits

● Sponsor: Supernus
● General Summary: Real-World Patient Experiences Using Continuous Subcutaneous
● Apomorphine Infusion (ONAPGO) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
● Study Product: Continuous subcutaneous apomorphine infusion used with Levodopa as adjunct
● Target Population:
● Length: ~52 weeks, 9 visits

● Sponsor: Parkinson's Foundation
● General Summary: Genetic study where they analyze the genetics in the participant's blood to see if there are any mutations related to Parkinson’s
● Target Population: Parkinson’s patients as well as family members who may be at risk for PD
● Length: 1 visit

● Sponsor: CND Life Sciences
● General Summary: CND Life Sciences is meeting this demand with the Syn-One Test®, which assesses the accumulation of pathological alpha-synuclein using straightforward and convenient 3mm skin punch biopsies. By analysis of three small skin punch biopsies, CND identifies, visualizes, and quantifies the presence of phosphorylated alpha-synuclein (P-SYN) within cutaneous nerve fibers, facilitating the diagnosis of neurological disorders. This enables clinicians to gain valuable, objective insight at an earlier stage of the disease.
● Target Population: Parkinson's disease and patients with REM sleep behavior disorder
● Length: 18 months, 4 visits
● Compensation: $250 for each completed visit and up to $45 for any travel related expenses for every onsite visit.

● Sponsor: Vima Therapeutics
● General Summary: Non-Interventional, Observational Trial to characterize motor function, disability, and disease severity in individuals with isolated dystonia.
● Target Population: Individuals with isolated dystonia.
● Length: ~4 months, 2 visits
● Compensation: $25 for each completed visit

● Sponsor: Neuron23
● General Summary: NEU-411-PD201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease (NEULARK)
● The study will evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of orally-administered NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity as compared to placebo
● Study Product: NEU-411, Tablets
● Target Population: 40-80 y/o early PD patients currently not on any CD-LD therapy, with LRRK2 mutation
● Length: ~13 months, 20 visits
● Compensation: $25 for each completed visit

● Sponsor: TrueBinding Inc.
● General Summary: TB006PD2101: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson’s DiseaseThe study will evaluate the IP (TB006) dose-related safety in participants with PD and its efficacy in improving participants’ motor symptoms.
● Study Product: TB006, disease-modifying monoclonal antibody targeting Galectin-3
● TB006 is an experimental, humanized monoclonal antibody. It targets a protein called galectin-3. Galactin-3 is being studied for its potential role in inflammation and the formation of amyloid plaques.
● Because TB006 addresses both protein aggregation and neuroinflammation—key drivers in the progression of both AD and PD—it is a promising candidate for treating Parkinson's
● TB006 aims to reduce neuroinflammation, prevent protein clumping, and protect dopamine-producing neurons, which would potentially lead to improved motor function and a slowing of disease progression
● IV Infusion: 1-2 hours of continuous IV
● Target Population: Adult participants aged 50 to 80 years with PD, with <5 years since initial PD diagnosis
● Length: ~32 weeks